Carl O Landgren, MD, PhD
University of Miami
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carl O Landgren, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06100237 · Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)Carl Ola Landgren, MD, PhD · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT05896228 · Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaBenjamin T Diamond, MD · recruiting · Refractory Multiple Myeloma, Relapsed Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in multiple myeloma.